Research study Program year 2023 Source: CMS Open Payments

Darolutamide Roll Over Study

Research payments

$769,908

317 payments

Through program year 2023, $769,908 in research payments was reported against Darolutamide Roll Over Study, across 317 payments, paid by Bayer HealthCare Pharmaceuticals Inc..

Paid by: Bayer HealthCare Pharmaceuticals Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$332,353	169
2022	Research	$421,051	141
2020	Research	$16,504	7

Breakdown

Who paid Research payments · program years 2020–2023

Bayer HealthCare Pharmaceuticals Inc. $769,908 317 payments

Who received the money Research payments · program years 2020–2023

Henry Ford Pharmacy-Troy Organisation paid for research $51,893 13 payments
Johns Hopkins University Central Lockbox Organisation paid for research $44,748 8 payments
Gu Research Network, LLC Organisation paid for research $44,667 26 payments
Norton Healthcare INC Organisation paid for research $44,085 12 payments
University Of Rochester Organisation paid for research $42,980 11 payments
University Of Utah Organisation paid for research $40,111 13 payments
The Pennsylvania State University Organisation paid for research $35,491 14 payments
The Ohio State University Organisation paid for research $34,625 13 payments
Urology Clinics Of North Texas Organisation paid for research $30,334 1 payment
Biomedical Research Alliance Of New York LLC Organisation paid for research $25,815 14 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

9 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.